{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038547","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.718425+00:00","generated_at":"2026-05-17T17:51:52.485817+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.77,"calibrated_materiality_score":0.77,"confidence":"high","headline":"Zai Lab Q2 revenue grows 9% YoY to $110M; operating loss improves 28%; targets Q4 profitability","bullets":["Product revenue $109.1M (+9% YoY); VYVGART sales $26.5M (+46% QoQ); ZEJULA $41.0M (down from $45M YoY).","GAAP operating loss $54.9M (improved 28% YoY); adjusted operating loss $34.2M (improved 37% YoY).","Net loss $40.7M vs $80.3M YoY; cash $832.3M as of June 30, 2025.","Reaffirms FY2025 revenue guidance $560M-$590M; on track for adjusted profitability in Q4 2025.","Pipeline: ZL-1310 ORR 79% at 1.6mg/kg in 2L ES-SCLC; bemarituzumab Phase 3 met OS endpoint; China submission H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038547","json":"https://secwatch.observer/filing/0001628280-25-038547.json","markdown":"https://secwatch.observer/filing/0001628280-25-038547.md","text":"https://secwatch.observer/filing/0001628280-25-038547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828025038547/0001628280-25-038547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828025038547/zlab-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:51:52.485817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}